

Stefania Gori

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/631797/publications.pdf>

Version: 2024-02-01

192
papers

7,148
citations

87723

38
h-index

69108

77
g-index

199
all docs

199
docs citations

199
times ranked

9341
citing authors

#	ARTICLE	IF	CITATIONS
1	Multicenter Phase II Study of Lapatinib in Patients with Brain Metastases from HER2-Positive Breast Cancer. <i>Clinical Cancer Research</i> , 2009, 15, 1452-1459.	3.2	592
2	Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study. <i>Lancet Oncology</i> , The, 2009, 10, 943-949.	5.1	538
3	Overview of the Randomized Trials of Radiotherapy in Ductal Carcinoma In Situ of the Breast. <i>Journal of the National Cancer Institute Monographs</i> , 2010, 2010, 162-177.	0.9	511
4	Effect of the Gonadotropin-Releasing Hormone Analogue Triptorelin on the Occurrence of Chemotherapy-Induced Early Menopause in Premenopausal Women With Breast Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2011, 306, 269-76.	3.8	311
5	Adjuvant chemotherapy in oestrogen-receptor-poor breast cancer: patient-level meta-analysis of randomised trials. <i>Lancet</i> , The, 2008, 371, 29-40.	6.3	243
6	Prevalence of malnutrition in patients at first medical oncology visit: the PreMiO study. <i>Oncotarget</i> , 2017, 8, 79884-79896.	0.8	239
7	CEREBEL (EGF111438): A Phase III, Randomized, Open-Label Study of Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, 1564-1573.	0.8	201
8	Ovarian Suppression With Triptorelin During Adjuvant Breast Cancer Chemotherapy and Long-term Ovarian Function, Pregnancies, and Disease-Free Survival. <i>JAMA - Journal of the American Medical Association</i> , 2015, 314, 2632.	3.8	180
9	Anthracycline-induced cardiotoxicity: A multicenter randomised trial comparing two strategies for guiding prevention with enalapril: The International CardioOncology Society-oneÂtrial. <i>European Journal of Cancer</i> , 2018, 94, 126-137.	1.3	163
10	Clinical outcome of patients with brain metastases from HER2-positive breast cancer treated with lapatinib and capecitabine. <i>Annals of Oncology</i> , 2011, 22, 625-630.	0.6	146
11	Central Nervous System Metastases in HER2-Positive Metastatic Breast Cancer Patients Treated with Trastuzumab: Incidence, Survival, and Risk Factors. <i>Oncologist</i> , 2007, 12, 766-773.	1.9	132
12	Final results of a multicenter phase II clinical trial evaluating the activity of single-agent lapatinib in patients with HER2-negative metastatic breast cancer and HER2-positive circulating tumor cells. A proof-of-concept study. <i>Breast Cancer Research and Treatment</i> , 2012, 134, 283-289.	1.1	101
13	Gut microbiota and cancer: How gut microbiota modulates activity, efficacy and toxicity of antitumoral therapy. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 143, 139-147.	2.0	100
14	Evaluation of serum HER2 extracellular domain in early breast cancer patients: correlation with clinicopathological parameters and survival. <i>Annals of Oncology</i> , 2008, 19, 883-890.	0.6	93
15	CSF Concentration of Crizotinib in Two ALK-Positive Non-Small-Cell Lung Cancer Patients with CNS Metastases Deriving Clinical Benefit from Treatment. <i>Journal of Thoracic Oncology</i> , 2015, 10, e26-e27.	0.5	93
16	Neuroendocrine Carcinoma of the Breast: Current Evidence and Future Perspectives. <i>Oncologist</i> , 2016, 21, 28-32.	1.9	92
17	Trastuzumab Adjuvant Chemotherapy and Cardiotoxicity in Real-World Women With Breast Cancer. <i>Journal of Cardiac Failure</i> , 2012, 18, 113-119.	0.7	91
18	Effect of concomitant medications with immune-modulatory properties on the outcomes of patients with advanced cancer treated with immune checkpoint inhibitors: development and validation of a novel prognostic index. <i>European Journal of Cancer</i> , 2021, 142, 18-28.	1.3	81

#	ARTICLE	IF	CITATIONS
19	Contribution of <i>KRAS</i> mutations and c.2369C > T (p.T790M) <i>EGFR</i> to acquired resistance to EGFR-TKIs in <i>EGFR</i> mutant NSCLC: a study on circulating tumor DNA. <i>Oncotarget</i> , 2017, 8, 13611-13619.	0.8	81
20	Programmed Death Ligand 1 (PD-L1) as a Predictive Biomarker for Pembrolizumab Therapy in Patients with Advanced Non-Small-Cell Lung Cancer (NSCLC). <i>Advances in Therapy</i> , 2019, 36, 2600-2617.	1.3	80
21	Evaluation of the Prognostic Role of Vascular Endothelial Growth Factor and Microvessel Density in Stages I and II Breast Cancer Patients. <i>Breast Cancer Research and Treatment</i> , 2003, 81, 159-168.	1.1	78
22	Germ cell tumours of the testis. <i>Critical Reviews in Oncology/Hematology</i> , 2005, 53, 141-164.	2.0	77
23	CYP17, GSTP1, PON1 and GLO1 gene polymorphisms as risk factors for breast cancer: an Italian case-control study. <i>BMC Cancer</i> , 2009, 9, 115.	1.1	73
24	The molecular profiling of solid tumors by liquid biopsy: a position paper of the AIOM "SIAPEC-IAP" "SIBioC" "SIC" "SIF Italian Scientific Societies. <i>ESMO Open</i> , 2021, 6, 100164.	2.0	69
25	Neuroendocrine differentiation in breast carcinoma: clinicopathological features and outcome. <i>Histopathology</i> , 2016, 68, 422-432.	1.6	62
26	EGFR, pMAPK, pAkt and PTEN status by immunohistochemistry: correlation with clinical outcome in HER2-positive metastatic breast cancer patients treated with trastuzumab. <i>Annals of Oncology</i> , 2009, 20, 648-654.	0.6	61
27	Cardiotoxicity of Aromatase Inhibitors in Breast Cancer Patients. <i>Clinical Breast Cancer</i> , 2017, 17, 11-17.	1.1	60
28	Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of $\geq 50\%$. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 2209-2221.	2.0	60
29	Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial. <i>Lancet Oncology</i> , 2018, 19, 474-485.	5.1	59
30	Phase II study of weekly paclitaxel and trastuzumab in anthracycline- and taxane-pretreated patients with HER2-overexpressing metastatic breast cancer. <i>British Journal of Cancer</i> , 2004, 90, 36-40.	2.9	56
31	Weekly docetaxel versus CMF as adjuvant chemotherapy for older women with early breast cancer: final results of the randomized phase III ELDA trial. <i>Annals of Oncology</i> , 2015, 26, 675-682.	0.6	56
32	Adjuvant trastuzumab cardiotoxicity in patients over 60 years of age with early breast cancer: a multicenter cohort analysis. <i>Annals of Oncology</i> , 2012, 23, 3058-3063.	0.6	55
33	Efficacy and Safety of Zoledronic Acid in Patients with Breast Cancer Metastatic to Bone: A Multicenter Clinical Trial. <i>Oncologist</i> , 2006, 11, 841-848.	1.9	52
34	Pathogenesis, Clinical Manifestations and Management of Immune Checkpoint Inhibitors Toxicity. <i>Tumori</i> , 2017, 103, 405-421.	0.6	52
35	Breast cancer in elderly women: a different reality? Results from the NORA study. <i>Annals of Oncology</i> , 2007, 18, 991-996.	0.6	51
36	Recommendations for the implementation of BRCA testing in ovarian cancer patients and their relatives. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 140, 67-72.	2.0	51

#	ARTICLE	IF	CITATIONS
37	Role of renal function on the development of cardiotoxicity associated with trastuzumab-based adjuvant chemotherapy for early breast cancer. <i>Internal and Emergency Medicine</i> , 2012, 7, 439-446.	1.0	45
38	Extended therapy with letrozole as adjuvant treatment of postmenopausal patients with early-stage breast cancer: a multicentre, open-label, randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2021, 22, 1458-1467.	5.1	41
39	The tumor-agnostic treatment for patients with solid tumors: a position paper on behalf of the AIOM-SIAPEC/IAP-SIBioC-SIF Italian Scientific Societies. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 165, 103436.	2.0	40
40	Adjuvant zoledronic acid and letrozole plus ovarian function suppression in premenopausal breast cancer: HOBEO phase 3 randomised trial. <i>European Journal of Cancer</i> , 2019, 118, 178-186.	1.3	39
41	A phase 2 study of temozolomide in pretreated metastatic colorectal cancer with MGMT promoter methylation. <i>British Journal of Cancer</i> , 2017, 116, 1279-1286.	2.9	37
42	Follow-up of patients with early breast cancer: Is it time to rewrite the story?. <i>Critical Reviews in Oncology/Hematology</i> , 2014, 91, 130-141.	2.0	36
43	Prevalence, characteristics, and treatment of fatigue in oncological cancer patients in Italy: a cross-sectional study of the Italian Network for Supportive Care in Cancer (NICSO). <i>Supportive Care in Cancer</i> , 2019, 27, 1041-1047.	1.0	35
44	The lung immuno-oncology prognostic score (LIPS-3): a prognostic classification of patients receiving first-line pembrolizumab for PD-L1 ≥ 50% advanced non-small-cell lung cancer. <i>ESMO Open</i> , 2021, 6, 100078.	2.0	35
45	Modern radiotherapy in cancer treatment during pregnancy. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 136, 13-19.	2.0	33
46	“Triple positive” early breast cancer: an observational multicenter retrospective analysis of outcome. <i>Oncotarget</i> , 2016, 7, 17932-17944.	0.8	33
47	Retreatment with trastuzumab-based therapy after disease progression following lapatinib in HER2-positive metastatic breast cancer. <i>Annals of Oncology</i> , 2012, 23, 1436-1441.	0.6	31
48	Extended survival of a HER-2-positive metastatic breast cancer patient with brain metastases also treated with intrathecal trastuzumab. <i>Cancer Chemotherapy and Pharmacology</i> , 2009, 63, 1157-1159.	1.1	30
49	Radiation dose intensification in pre-operative chemo-radiotherapy for locally advanced rectal cancer. <i>Clinical and Translational Oncology</i> , 2017, 19, 189-196.	1.2	30
50	Intensity modulated radiation therapy with simultaneous integrated boost in early breast cancer irradiation. Report of feasibility and preliminary toxicity. <i>Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique</i> , 2015, 19, 289-294.	0.6	29
51	Association of Plasma Ceramides With Myocardial Perfusion in Patients With Coronary Artery Disease Undergoing Stress Myocardial Perfusion Scintigraphy. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2018, 38, 2854-2861.	1.1	29
52	Lapatinib concentration in cerebrospinal fluid in two patients with HER2-positive metastatic breast cancer and brain metastases. <i>Annals of Oncology</i> , 2014, 25, 912-913.	0.6	28
53	Approach to hyponatremia according to the clinical setting: Consensus statement from the Italian Society of Endocrinology (SIE), Italian Society of Nephrology (SIN), and Italian Association of Medical Oncology (AIOM). <i>Journal of Endocrinological Investigation</i> , 2018, 41, 3-19.	1.8	28
54	Identification of Subgroups of Early Breast Cancer Patients at High Risk of Nonadherence to Adjuvant Hormone Therapy: Results of an Italian Survey. <i>Clinical Breast Cancer</i> , 2015, 15, e131-e137.	1.1	27

#	ARTICLE	IF	CITATIONS
55	Role of MGMT as biomarker in colorectal cancer. <i>World Journal of Clinical Cases</i> , 2014, 2, 835.	0.3	27
56	Position Paper of the Italian Association of Medical Oncology on Early Palliative Care in Oncology Practice (Simultaneous Care). <i>Tumori</i> , 2017, 103, 9-14.	0.6	26
57	Rechallenge of immune checkpoint inhibitors: A systematic review and meta-analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 165, 103434.	2.0	26
58	The challenge of the Molecular Tumor Board empowerment in clinical oncology practice: A Position Paper on behalf of the AIOM- SIAPEC/IAP-SIBioC-SIC-SIF-SIGU-SIRM Italian Scientific Societies. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 169, 103567.	2.0	26
59	Ductal carcinoma in situ with microinvasion: Clinicopathologic study and biopathologic profile. <i>Pathology Research and Practice</i> , 2006, 202, 131-135.	1.0	25
60	Alectinib™s activity against CNS metastases from ALK-positive non-small cell lung cancer: a single institution case series. <i>Journal of Neuro-Oncology</i> , 2016, 129, 355-361.	1.4	25
61	Survival of Patients Treated with Antibiotics and Immunotherapy for Cancer: A Systematic Review and Meta-Analysis. <i>Journal of Clinical Medicine</i> , 2020, 9, 1458.	1.0	24
62	Predictive ability of a drug-based score in patients with advanced non-small-cell lung cancer receiving first-line immunotherapy. <i>European Journal of Cancer</i> , 2021, 150, 224-231.	1.3	24
63	Weekly docetaxel versus CMF as adjuvant chemotherapy for elderly breast cancer patients: Safety data from the multicentre phase 3 randomised ELDA trial. <i>Critical Reviews in Oncology/Hematology</i> , 2008, 66, 171-180.	2.0	23
64	Role of hypertension on new onset congestive heart failure in patients receiving trastuzumab therapy for breast cancer. <i>Journal of Cardiovascular Medicine</i> , 2014, 15, 141-146.	0.6	23
65	Denosumab for bone health in prostate and breast cancer patients receiving endocrine therapy? A systematic review and a meta-analysis of randomized trials. <i>Journal of Bone Oncology</i> , 2019, 18, 100252.	1.0	23
66	Impact of Metformin Use and Diabetic Status During Adjuvant Fluoropyrimidine-Oxaliplatin Chemotherapy on the Outcome of Patients with Resected Colon Cancer: A TOSCA Study Subanalysis. <i>Oncologist</i> , 2019, 24, 385-393.	1.9	23
67	Pharmacotherapeutic options for treating brain metastases in non-small cell lung cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2015, 16, 2601-2613.	0.9	22
68	Inclusion of Platinum Agents in Neoadjuvant Chemotherapy Regimens for Triple-Negative Breast Cancer Patients: Development of GRADE (Grades of Recommendation, Assessment, Development and) <i>Tj ETQq0 0 0 rgBT /Overlock 10 T</i> 1137.	1.78	22
69	Impact of 21-Gene Breast Cancer Assay on Treatment Decision for Patients with T1-T3, N0-N1, Estrogen Receptor-Positive/Human Epidermal Growth Receptor 2-Negative Breast Cancer: Final Results of the Prospective Multicenter ROXANE Study. <i>Oncologist</i> , 2019, 24, 1424-1431.	1.9	22
70	Immune Checkpoint Inhibitors and Atherosclerotic Vascular Events in Cancer Patients. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 652186.	1.1	22
71	Capecitabine and Temozolomide versus FOLFIRI in RAS-Mutated, MGMT-Methylated Metastatic Colorectal Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 1017-1024.	3.2	22
72	Low-dose aminoglutethimide with and without hydrocortisone replacement as a first-line endocrine treatment in advanced breast cancer: a prospective randomized trial of the Italian Oncology Group for Clinical Research.. <i>Journal of Clinical Oncology</i> , 1992, 10, 984-989.	0.8	21

#	ARTICLE	IF	CITATIONS
73	Recommendations for the implementation of <i>BRCA</i> testing in the care and treatment pathways of ovarian cancer patients. <i>Future Oncology</i> , 2016, 12, 2071-2075.	1.1	21
74	Induction Chemotherapy with Cisplatin, Doxorubicin, and Cyclophosphamide (CAP) in a Combined Modality Approach for Locally Advanced and Inflammatory Breast Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 1996, 19, 10-17.	0.6	21
75	HER2 Overexpression as a Predictive Marker in a Randomized Trial Comparing Adjuvant Cyclophosphamide/Methotrexate/5-Fluorouracil with Epirubicin in Patients with Stage I/II Breast Cancer: Long-Term Results. <i>Clinical Breast Cancer</i> , 2005, 6, 253-259.	1.1	20
76	State of the art of chemotherapy for the treatment of central nervous system metastases from non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2016, 5, 599-609.	1.3	20
77	Early prediction of pancreatic cancer from new-onset diabetes: an Associazione Italiana Oncologia Medica (AIOM)/Associazione Medici Diabetologi (AMD)/Societ� Italiana Endocrinologia (SIE)/Societ� Italiana Farmacologia (SIF) multidisciplinary consensus position paper. <i>ESMO Open</i> , 2021, 6, 100155.	2.0	20
78	Expander/implant breast reconstruction before radiotherapy. <i>Strahlentherapie Und Onkologie</i> , 2012, 188, 1074-1079.	1.0	19
79	Do cancer patients change their diet in the e-health information era? A review of the literature and a survey as a proposal for the Italian population. <i>Food Research International</i> , 2018, 104, 59-68.	2.9	19
80	Immune checkpoint inhibitors-associated pericardial disease: a systematic review of case reports. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 3041-3053.	2.0	19
81	Post-progression outcomes of NSCLC patients with PD-L1 expression � 50% receiving first-line single-agent pembrolizumab in a large multicentre real-world study. <i>European Journal of Cancer</i> , 2021, 148, 24-35.	1.3	19
82	Weekly Paclitaxel in Metastatic Breast Cancer Patients: A Phase II Study. <i>Tumori</i> , 2002, 88, 470-473.	0.6	18
83	Comorbidities and intensity-modulated radiotherapy with simultaneous integrated boost in elderly breast cancer patients. <i>Aging Clinical and Experimental Research</i> , 2018, 30, 533-538.	1.4	18
84	The Breast Avastin Trial: phase II study of bevacizumab maintenance therapy after induction chemotherapy with docetaxel and capecitabine for the first-line treatment of patients with locally recurrent or metastatic breast cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2013, 71, 1051-1057.	1.1	17
85	Failure of dihydroartemisinin-piperaquine treatment of uncomplicated Plasmodium falciparum malaria in a traveller coming from Ethiopia. <i>Malaria Journal</i> , 2016, 15, 525.	0.8	17
86	The evolving landscape of criteria for evaluating tumor response in the era of cancer immunotherapy: From Karnofsky to iRECIST. <i>Tumori</i> , 2018, 104, 88-95.	0.6	17
87	Epidermal growth factor receptor gene copy number may predict lapatinib sensitivity in HER2-positive metastatic breast cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2013, 14, 699-706.	0.9	16
88	18F-NaF PET/CT Imaging of Brain Metastases. <i>Clinical Nuclear Medicine</i> , 2016, 41, 564-565.	0.7	16
89	Circulating biomarkers and cardiac function over 3 years after chemotherapy with anthracyclines: the ICOS ONE trial. <i>ESC Heart Failure</i> , 2020, 7, 1452-1466.	1.4	16
90	Pharmacokinetics of Oxaliplatin in a Hemodialyzed Patient: Chemotherapy Dose Adjustment and Timing of Dialysis. <i>Clinical Colorectal Cancer</i> , 2014, 13, 260-263.	1.0	15

#	ARTICLE	IF	CITATIONS
91	Early Integration of Palliative Care in Oncology Practice: Results of the Italian Association of Medical Oncology (AIOM) Survey. <i>Journal of Cancer</i> , 2016, 7, 1968-1978.	1.2	15
92	Association between plasma ceramides and inducible myocardial ischemia in patients with established or suspected coronary artery disease undergoing myocardial perfusion scintigraphy. <i>Metabolism: Clinical and Experimental</i> , 2018, 85, 305-312.	1.5	15
93	Moving the Target on the Optimal Adjuvant Strategy for Resected Pancreatic Cancers: A Systematic Review with Meta-Analysis. <i>Cancers</i> , 2020, 12, 534.	1.7	15
94	Epidemiology and clinical course of severe acute respiratory syndrome coronavirus 2 infection in cancer patients in the Veneto Oncology Network: The Rete Oncologica Veneta covid19 study. <i>European Journal of Cancer</i> , 2021, 147, 120-127.	1.3	15
95	Epirubicin versus CMF as adjuvant therapy for stage I and II breast cancer: a prospective randomised study. <i>European Journal of Cancer</i> , 2002, 38, 2279-2288.	1.3	14
96	Importance of adherence to guidelines in breast cancer clinical practice. The Italian experience (AIOM). <i>Tumori</i> , 2011, 97, 559-563.	0.6	14
97	Trastuzumab quantification in serum: a new, rapid, robust ELISA assay based on a mimetic peptide that specifically recognizes trastuzumab. <i>Analytical and Bioanalytical Chemistry</i> , 2014, 406, 4557-4561.	1.9	14
98	Symptomatic COVID-19 in advanced-cancer patients treated with immune-checkpoint inhibitors: prospective analysis from a multicentre observational trial by FICOG. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592096846.	1.4	14
99	The Impact of the SARS-CoV-2 Outbreak on the Psychological Flexibility and Behaviour of Cancelling Medical Appointments of Italian Patients with Pre-Existing Medical Condition: The "ImpACT-COVID-19 for Patients" Multi-Centre Observational Study. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 340.	1.2	14
100	Current treatment options for HER2-positive breast cancer patients with brain metastases. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 161, 103329.	2.0	14
101	PD-1/PD-L1 checkpoint inhibitors during late stages of life: an ad-hoc analysis from a large multicenter cohort. <i>Journal of Translational Medicine</i> , 2021, 19, 270.	1.8	14
102	Influence of chemotherapeutic drug-related gene polymorphisms on toxicity and survival of early breast cancer patients receiving adjuvant chemotherapy. <i>BMC Cancer</i> , 2017, 17, 502.	1.1	13
103	Antineoplastic dosing in overweight and obese cancer patients; an Associazione Italiana Oncologia Medica (AIOM)/Associazione Medici Diabetologi (AMD)/Societ� Italiana Endocrinologia (SIE)/Societ� Italiana Farmacologia (SIF) multidisciplinary consensus position paper. <i>ESMO Open</i> , 2021, 6, 100153.	2.0	13
104	Adjuvant chemotherapy of pT1a and pT1b breast carcinoma: results from the NEMESI study. <i>BMC Cancer</i> , 2012, 12, 158.	1.1	12
105	A new informed consent form model for cancer patients: Preliminary results of a prospective study by the Italian Association of Medical Oncology (AIOM). <i>Patient Education and Counseling</i> , 2012, 87, 243-249.	1.0	12
106	Pharmacogenetics and aromatase inhibitor induced side effects in breast cancer patients. <i>Pharmacogenomics</i> , 2017, 18, 821-830.	0.6	12
107	Phase II study of eribulin in combination with gemcitabine for the treatment of patients with locally advanced or metastatic triple negative breast cancer (ERIGE trial). Clinical and pharmacogenetic results on behalf of the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC). <i>ESMO Open</i> , 2021, 6, 100019.	2.0	12
108	Metabolic disorders and gastroenteropancreatic-neuroendocrine tumors (GEP-NETS): How do they influence each other? An Italian Association of Medical Oncology (AIOM)/ Italian Association of Medical Diabetologists (AMD)/ Italian Society of Endocrinology (SIE)/ Italian Society of Pharmacology (SIF) multidisciplinary consensus position paper. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 169, 103572.	2.0	12

#	ARTICLE	IF	CITATIONS
109	Safety of Epirubicin Adjuvant Chemotherapy in a Breast Cancer Patient with Chronic Renal Failure Undergoing Hemodialytic Treatment. <i>Tumori</i> , 2006, 92, 364-365.	0.6	11
110	Agreement between oncology guidelines and clinical practice in Italy: the "right"™ program. A project of the Italian Association of Medical Oncology (AIOM). <i>Annals of Oncology</i> , 2007, 18, vi179-vi184.	0.6	11
111	The Promher Study: An Observational Italian Study on Adjuvant Therapy for HER2-Positive, pT1a-b pNO Breast Cancer. <i>PLoS ONE</i> , 2015, 10, e0136731.	1.1	11
112	The 41-gene classifier TRAR predicts response of HER2 positive breast cancer patients in the NeoALTTO study. <i>European Journal of Cancer</i> , 2019, 118, 1-9.	1.3	11
113	The HERBA Study: A Retrospective Multi-Institutional Italian Study on Patients With Brain Metastases From HER2-Positive Breast Cancer. <i>Clinical Breast Cancer</i> , 2019, 19, e501-e510.	1.1	11
114	Clinical outcomes of NSCLC patients experiencing early immune-related adverse events to PD-1/PD-L1 checkpoint inhibitors leading to treatment discontinuation. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 865-874.	2.0	11
115	Chemotherapy with cis-Platin, Doxorubicin, and Cyclophosphamide (CAP) in Patients with Metastatic Breast Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 1989, 12, 137-141.	0.6	10
116	ERCC1 expression in triple negative breast carcinoma: the paradox revisited. <i>Breast Cancer Research and Treatment</i> , 2008, 111, 569-570.	1.1	10
117	Fentanyl pectin nasal spray for painful mucositis in head and neck cancers during intensity-modulated radiation therapy with or without chemotherapy. <i>Clinical and Translational Oncology</i> , 2017, 19, 593-598.	1.2	10
118	Adjuvant endocrine therapy in premenopausal patients with hormone receptor-positive early breast cancer: Evidence evaluation and GRADE recommendations by the Italian Association of Medical Oncology (AIOM). <i>European Journal of Cancer</i> , 2018, 99, 9-19.	1.3	10
119	Management of kidney cancer patients: 2018 guidelines of the Italian Medical Oncology Association (AIOM). <i>Tumori</i> , 2019, 105, 3-12.	0.6	10
120	An update on the conquests and perspectives of cardio-oncology in the field of tumor angiogenesis-targeting TKI-based therapy. <i>Expert Opinion on Drug Safety</i> , 2019, 18, 485-496.	1.0	10
121	Standard (8%weeks) vs long (12%weeks) timing to minimally-invasive surgery after NeoAdjuvant Chemoradiotherapy for rectal cancer: a multicenter randomized controlled parallel group trial (TiMiSNAR). <i>BMC Cancer</i> , 2019, 19, 1215.	1.1	10
122	Challenges and advances for the treatment of renal cancer patients with brain metastases: From immunological background to upcoming clinical evidence on immune-checkpoint inhibitors. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 163, 103390.	2.0	10
123	Identification of Non-Traumatic Bone Marrow Oedema: The Pearls and Pitfalls of Dual-Energy CT (DECT). <i>Tomography</i> , 2021, 7, 387-396.	0.8	10
124	Benefit from letrozole as extended adjuvant therapy after sequential endocrine therapy: A randomized, phase III study of Gruppo Italiano Mammella (GIM).. <i>Journal of Clinical Oncology</i> , 2019, 37, 504-504.	0.8	10
125	Results of the ECHO (Eating habits CHanges in Oncologic patients) Survey: An Italian Cross-Sectional Multicentric Study to Explore Dietary Changes and Dietary Supplement Use, in Breast Cancer Survivors. <i>Frontiers in Oncology</i> , 2021, 11, 705927.	1.3	10
126	An integrated care pathway for cancer patients with diabetes: A proposal from the Italian experience. <i>Diabetes Research and Clinical Practice</i> , 2020, 159, 107721.	1.1	9

#	ARTICLE	IF	CITATIONS
127	Evaluating the role of FAMILY history of cancer and diagnosis of multiple neoplasms in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: the multicenter FAMI-L1 study. <i>Oncolimmunology</i> , 2020, 9, 1710389.	2.1	9
128	Acute kidney injury from contrast-enhanced CT procedures in patients with cancer: white paper to highlight its clinical relevance and discuss applicable preventive strategies. <i>ESMO Open</i> , 2020, 5, e000618.	2.0	9
129	Long-Term Results in Patients with Advanced Epithelial Ovarian Carcinoma Treated with a Combination of Cisplatin, Doxorubicin, and Cyclophosphamide. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 1997, 20, 522-526.	0.6	9
130	Weekly paclitaxel in metastatic breast cancer patients: a phase II study. <i>Tumori</i> , 2002, 88, 470-3.	0.6	9
131	Salvage chemotherapy in metastatic breast cancer: An experience with the combination of mitoxantrone, 5-fluorouracil, and L-leucovorin. <i>Breast Cancer Research and Treatment</i> , 1996, 38, 277-282.	1.1	8
132	A population survival model for breast cancer. <i>Breast</i> , 2005, 14, 94-102.	0.9	8
133	Effectiveness of neoadjuvant trastuzumab and chemotherapy in HER2-overexpressing breast cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2013, 139, 1229-1240.	1.2	8
134	Clinical and Organizational Issues in the Management of Surviving Breast and Colorectal Cancer Patients: Attitudes and Feelings of Medical Oncologists. <i>PLoS ONE</i> , 2014, 9, e101170.	1.1	8
135	First Prospective Multicenter Italian Study on the Impact of the 21â€Gene Recurrence Score in Adjuvant Clinical Decisions for Patients with ER Positive/HER2 Negative Breast Cancer. <i>Oncologist</i> , 2018, 23, 297-305.	1.9	8
136	Schlafen-11 (SLFN11): a step forward towards personalized medicine in small-cell lung cancer?. <i>Translational Lung Cancer Research</i> , 2018, 7, S341-S345.	1.3	8
137	Safety profile of subcutaneous trastuzumab for the treatment of patients with HER2-positive early or locally advanced breast cancer: primary analysis of the SCHEARLY study. <i>European Journal of Cancer</i> , 2018, 105, 61-70.	1.3	8
138	Efficacy of immune checkpoint inhibitors in elderly patients agedâ€75Âyears. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 1777-1780.	2.0	8
139	Everolimus plus aromatase inhibitors as maintenance therapy after first-line chemotherapy: Final results of the phase III randomised MAIN-A (MAINtenance Afinitor) trial. <i>European Journal of Cancer</i> , 2021, 154, 21-29.	1.3	8
140	Breast Cancer â€Tailored Follow-upâ€in Italian Oncology Units: A Web-Based Survey. <i>PLoS ONE</i> , 2014, 9, e94063.	1.1	8
141	Management of oral anticancer drugs: feasibility and patient approval of a specific monitoring program. <i>Tumori</i> , 2014, 100, 243-8.	0.6	8
142	Management of metabolic adverse events of targeted therapies and immune checkpoint inhibitors in cancer patients: an Associazione Italiana Oncologia Medica (AIOM)/Associazione Medici Diabetologi (AMD)/Societ� Italiana Farmacologia (SIF) multidisciplinary consensus position paper. <i>Critical Reviews in Oncology/Hematology</i> , 2020, 154, 103066.	2.0	7
143	Host immuneâ€inflammatory markers to unravel the heterogeneous outcome and assessment of patients with <sc>PDâ€L1</sc> â€50% metastatic nonâ€small cell lung cancer and poor performance status receiving firstâ€line immunotherapy. <i>Thoracic Cancer</i> , 2022, 13, 483-488.	0.8	7
144	Vindesine and mitomycin c in chemotherapy refractory advanced breast cancer. <i>Cancer</i> , 1986, 57, 904-907.	2.0	6

#	ARTICLE	IF	CITATIONS
145	Long-Lasting Complete Remission with Tyrosine Kinase Inhibitor in Bronchioloalveolar Carcinoma with a so far Unknown EGFR Mutation. <i>Journal of Thoracic Oncology</i> , 2008, 3, 452-453.	0.5	6
146	Biological characterization and selection criteria of adjuvant chemotherapy for early breast cancer: experience from the Italian observational NEMESI study. <i>BMC Cancer</i> , 2012, 12, 216.	1.1	6
147	HER-3 Status by Immunohistochemistry in HER-2-Positive Metastatic Breast Cancer Patients Treated with Trastuzumab: Correlation with Clinical Outcome. <i>Tumori</i> , 2012, 98, 39-44.	0.6	6
148	¹⁸ F-Sodium Fluoride PET-CT for the Assessment of Brain Metastasis from Lung Adenocarcinoma. <i>Journal of Thoracic Oncology</i> , 2015, 10, e67-e68.	0.5	6
149	Pharmacokinetics of Trastuzumab in Haemodialysis. <i>Breast Journal</i> , 2015, 21, 329-331.	0.4	6
150	The Critical Role of the Clinical Research Coordinator for Clinical Trials: A Survey in Oncology. <i>Medicine Access Point of Care</i> , 2017, 1, maapoc.0000015.	1.0	6
151	When and how to treat women with HER2-positive, small (pT1a-b), node-negative breast cancer?. <i>Critical Reviews in Oncology/Hematology</i> , 2018, 128, 130-138.	2.0	6
152	Metastatic breast cancers: Estimates for Italy. <i>Tumori</i> , 2018, 104, 116-120.	0.6	6
153	An Italian Delphi study to evaluate consensus on adjuvant endocrine therapy in premenopausal patients with breast cancer: the ERA project. <i>BMC Cancer</i> , 2018, 18, 932.	1.1	6
154	Postoperative Breast Radiotherapy after Neoadjuvant Chemotherapy: Which Uncertainties still Remain?. <i>Tumori</i> , 2014, 100, e212-e213.	0.6	6
155	Progesterone Receptor Status and Clinical Outcome in Breast Cancer Patients with Estrogen Receptor-Positive Locoregional Recurrence. <i>Tumori</i> , 2015, 101, 398-403.	0.6	5
156	Phase III study with FOLFIRI+ cetuximab versus FOLFIRI+ cetuximab followed by cetuximab alone in KRAS and BRAF WT mCRC. <i>Future Oncology</i> , 2018, 14, 1339-1346.	1.1	5
157	Endocrine therapy for hormone receptor-positive, HER2-negative metastatic breast cancer: extending endocrine sensitivity. <i>Future Oncology</i> , 2020, 16, 129-145.	1.1	5
158	From Diagnostic-Therapeutic Pathways to Real-World Data: A Multicenter Prospective Study on Upfront Treatment for EGFR-Positive Non-Small Cell Lung Cancer (MOST Study). <i>Oncologist</i> , 2019, 24, e318-e326.	1.9	5
159	High familial burden of cancer correlates with improved outcome from immunotherapy in patients with NSCLC independent of somatic DNA damage response gene status. <i>Journal of Hematology and Oncology</i> , 2022, 15, 9.	6.9	5
160	Coexpression of HER-2/neu and p53 in Breast Cancer Identifies a Subset with an Aggressive Biopathological Profile. <i>Tumori</i> , 2006, 92, 412-415.	0.6	4
161	Oral Chemotherapy and Patient Perspective in Solid Tumors: A National Survey by the Italian Association of Medical Oncology. <i>Tumori</i> , 2016, 102, 108-113.	0.6	4
162	Oxaliplatin plus fluoropyrimidines as adjuvant therapy for colon cancer in older patients: A subgroup analysis from the TOSCA trial. <i>European Journal of Cancer</i> , 2021, 148, 190-201.	1.3	4

#	ARTICLE	IF	CITATIONS
163	Sunitinib therapy in metastatic papillary thyroid cancer. <i>Tumori</i> , 2013, 99, 285e-7e.	0.6	4
164	Impact of use of Oral Anticancer Drugs on Activity of Italian Oncology Practices: Results of a Survey Conducted by the Italian Society of Medical Oncology (AIOM). <i>Tumori</i> , 2013, 99, 35-38.	0.6	3
165	Ethics in Oncology: Principles and Responsibilities Declared in the Italian Ragusa Statement. <i>Tumori</i> , 2016, 102, e25-e27.	0.6	3
166	Effectiveness of tapentadol prolonged release for the management of painful mucositis in head and neck cancers during intensity modulated radiation therapy. <i>Supportive Care in Cancer</i> , 2016, 24, 4451-4455.	1.0	3
167	BRCA1/2 Molecular Assay for Ovarian Cancer Patients: A Survey through Italian Departments of Oncology and Molecular and Genomic Diagnostic Laboratories. <i>Diagnostics</i> , 2019, 9, 146.	1.3	3
168	Management of hyperglycemia in oncological patients scheduled for an FDG-PET/CT examination. <i>Clinical and Translational Imaging</i> , 2019, 7, 447-450.	1.1	3
169	Feasibility of Eribulin Mesylate in older patients with locally advanced or metastatic breast cancer: A post-hoc analysis of the ESEMPIO study. <i>Journal of Geriatric Oncology</i> , 2019, 10, 990-993.	0.5	3
170	Phase I studies: a test bench for Italian clinical research. <i>Tumori</i> , 2020, 106, 295-300.	0.6	3
171	Oral anticancer therapy project: Clinical utility of a specific home care nursing programme on behalf of Italian Association of Medical Oncology (AIOM). <i>Journal of Clinical Nursing</i> , 2020, 29, 119-129.	1.4	3
172	Patient associations and clinical oncology research: how much does a patient's voice really matter?. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2021, 21, 433-440.	0.7	3
173	Second medical opinion in oncological setting. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 160, 103282.	2.0	3
174	Effectiveness of a Psychosocial Care Quality Improvement Strategy to Address Quality of Life in Patients With Cancer. <i>JAMA Network Open</i> , 2021, 4, e2128667.	2.8	3
175	Clinical profile and mortality of Sars-Cov-2 infection in cancer patients across two pandemic time periods (Feb 2020–Sep 2020; Sep 2020–May 2021) in the Veneto Oncology Network: The ROVID study. <i>European Journal of Cancer</i> , 2022, 167, 81-91.	1.3	3
176	HER-3 status by immunohistochemistry in HER-2-positive metastatic breast cancer patients treated with trastuzumab: correlation with clinical outcome. <i>Tumori</i> , 2012, 98, 39-44.	0.6	3
177	Lonidamine in Advanced Colorectal Cancer: A Phase II Study of the Italian Oncology Group for Clinical Research (Goirc). <i>Tumori</i> , 1989, 75, 277-279.	0.6	2
178	Interstitial high-dose-rate brachytherapy after breast conserving surgery. <i>Oncology Reports</i> , 2010, 24, 417-22.	1.2	2
179	Letter to the editor concerning Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exploratory analysis in EMILIA™. <i>Annals of Oncology</i> , 2015, 26, 1033-1034.	0.6	2
180	Predictive Factors of Lapatinib and Capecitabine Activity in Patients with HER2-Positive, Trastuzumab-Resistant Metastatic Breast Cancer: Results from the Italian Retrospective Multicenter HERLAPAC Study. <i>PLoS ONE</i> , 2016, 11, e0156221.	1.1	2

#	ARTICLE	IF	CITATIONS
181	Expression levels of circulating miRNAs as biomarkers during multimodal treatment of rectal cancer - TiMiSNAR-mirna: a substudy of the TiMiSNAR Trial (NCT03962088). <i>Trials</i> , 2020, 21, 678.	0.7	2
182	Pretreatment lung immune prognostic index as a biomarker in advanced non-small-cell lung cancer patients receiving first line pembrolizumab. <i>Immunotherapy</i> , 2021, 13, 1093-1103.	1.0	2
183	Results of a Prospective Study with High-dose Etoposide, Thiotepa and Carboplatin and Peripheral Blood Stem Cell Rescue for High-risk Stage II-IIIa and Selected Stage IV Breast Cancer Patients. <i>Tumori</i> , 2001, 87, 138-141.	0.6	1
184	Skip pattern approach toward the early access of innovative anticancer drugs. <i>ESMO Open</i> , 2021, 6, 100227.	2.0	1
185	Adherence to oral hormonal anticancer agents in breast cancer. <i>Tumori</i> , 2023, 109, 262-268.	0.6	1
186	T1-T2 Breast Cancer with Four or More Positive Axillary Lymph Nodes: Adjuvant Locoregional Radiotherapy with High-Dose or Standard-Dose Chemotherapy. Results of an Observational Study. <i>Tumori</i> , 2004, 90, 379-386.	0.6	0
187	Author's Reply to: Patient-centered Medicine in Palliative Cancer Care: The Impossible Choice between Physician's Responsibility and Patient's Preferences. <i>Tumori</i> , 2017, 103, e22-e22.	0.6	0
188	Central Nervous System Malignancies. <i>UNIPA Springer Series</i> , 2021, , 731-754.	0.1	0
189	Precision Medicine in Oncology: Glossary of Relevant Scientific Terms. <i>UNIPA Springer Series</i> , 2021, , 411-416.	0.1	0
190	Breast Cancer in Men: <i>Oncology</i> . , 2020, , 85-92.		0
191	Impact of use of oral anticancer drugs on activity of Italian oncology practices: results of a survey conducted by the Italian Society of Medical Oncology (AIOM). <i>Tumori</i> , 2013, 99, 35-8.	0.6	0
192	Efficacy of trastuzumab in unselected patients with HER2-positive metastatic breast cancer: a retrospective analysis. <i>Tumori</i> , 2014, 100, 426-31.	0.6	0